Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

HOUSTON--(BUSINESS WIRE)--Thorpe Corporation (thorpecorp.com) announced today that its subsidiary, Thorpe-Sunbelt, Inc., has completed the acquisition of Houston-based Blagrave & Duffey, Inc. ("B&D"), ...

Identify research insights to guide research strategy and grow your impact with our Nature Strategy reports. Actionable insights into research performance. Detailed analysis of strengths and ...